老年医学与保健2025，Vol.31Issue(3)：659-662,680,5.
利伐沙班与达比加群酯在老年非瓣膜病慢性房颤患者长期抗凝治疗中的效果对比
Comparison of effects of rivaroxaban and dabigatran in long-term anticoagulant therapy for elderly patients with non-valvular chronic atrial fibrillation
韩丹 1王子玉1
作者信息
- 1. 复旦大学附属华东医院药剂科,上海 200040
- 折叠
摘要
Abstract
Objective To investigate the efficacy of rivaroxaban and dabigatran in long-term anticoagulation therapy for elderly patients with non-valvular chronic atrial fibrillation(NVAF).Methods 82 NVAF patients admitted to Huadong Hospi-tal from January to October 2023 were selected and randomly divided into rivaroxaban group(Riva group)and dabigatran group(Dabi group),with 41 patients in each group.The coagulation function,liver and kidney function,thromboembolic events,bleeding events,and incidence of adverse reactions were compared between the two groups.Results There were no statistically significant differences in thrombin time(TT)and international normalized ratio(INR)between the two groups be-fore and after treatment(P＞0.05).The activated partial thrombin time(APTT)changed significantly during the treatment.At 3 months and 12 months of treatment,the APTT level of the Dabi group was higher than that of the Riva group(P＜0.05).There were no statistically significant differences in liver and kidney function,and the incidence of thromboembolic events,bleeding events and adverse reaction between the two groups(P＞0.05).Conclusion Both rivaroxaban and dabigatran dem-onstrate good anticoagulation efficacy and safety in elderly NVAF patients.关键词
老年/非瓣膜病/慢性房颤/利伐沙班/达比加群酯/抗凝治疗Key words
elderly/non-valvular disease/chronic atrial fibrillation/rivaroxaban/dabigatran/anticoagulation therapy引用本文复制引用
韩丹,王子玉..利伐沙班与达比加群酯在老年非瓣膜病慢性房颤患者长期抗凝治疗中的效果对比[J].老年医学与保健,2025,31(3):659-662,680,5.
